A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors

This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with chemotherapy or immunotherapy.

本研究为一项首次人体开放标签剂量爬坡试验，旨在评估培吉洛德卡（pegilodecakin）单药或联合化疗、免疫治疗每日皮下给药时，在晚期实体瘤受试者中的安全性与耐受性。